Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Original ArticleOriginal Article
Open Access

Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer

Ming Bai, Yao Lu, Chunmei Shi, Jianwei Yang, Wei Li, Xianli Yin, Chenghui Huang, Lin Shen, Liangzhi Xie and Yi Ba
Cancer Biology & Medicine July 2024, 21 (7) 636-650; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0301
Ming Bai
1Department of GI Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yao Lu
1Department of GI Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin 300060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunmei Shi
2Fujian Medical University Union Hospital, Fuzhou 350001, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianwei Yang
3Fujian Provincial Cancer Hospital, Fuzhou 350014, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Li
4Cancer Center, The First Hospital of Jilin University, Changchun 130021, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xianli Yin
5Department of Medical Oncology Gastroenterology and Urology, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chenghui Huang
6Department of Oncology, The Third Xiangya Hospital, Central South University, Changsha 410013, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin Shen
7Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liangzhi Xie
8Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Ba
1Department of GI Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin 300060, China
9Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100010, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yi Ba
  • For correspondence: bayi{at}tjmuch.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Information

vol. 21 no. 7 636-650
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2023.0301
PubMed 
38148327

Published By 
Cancer Biology & Medicine
History 
  • Received August 15, 2018
  • Accepted November 22, 2023
  • Published online July 25, 2024.

Article Versions

  • previous version (December 22, 2023 - 23:01).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright: © 2024, The Authors This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.

Author Information

  1. Ming Bai1,*,
  2. Yao Lu1,*,
  3. Chunmei Shi2,
  4. Jianwei Yang3,
  5. Wei Li4,
  6. Xianli Yin5,
  7. Chenghui Huang6,
  8. Lin Shen7,
  9. Liangzhi Xie8 and
  10. Yi Ba1,9⇑
  1. 1Department of GI Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin 300060, China
  2. 2Fujian Medical University Union Hospital, Fuzhou 350001, China
  3. 3Fujian Provincial Cancer Hospital, Fuzhou 350014, China
  4. 4Cancer Center, The First Hospital of Jilin University, Changchun 130021, China
  5. 5Department of Medical Oncology Gastroenterology and Urology, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China
  6. 6Department of Oncology, The Third Xiangya Hospital, Central South University, Changsha 410013, China
  7. 7Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China
  8. 8Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China
  9. 9Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100010, China
  1. Correspondence to: Yi Ba, E-mail: bayi{at}tjmuch.com
View Full Text

Funding

  • Tianjin Key Medical Discipline (Specialty) Construction Project

    TJYXZDXK-009A
  • National Natural Science Foundation of China

    82103677
  • National Science and Technology Major Projects of China

    2019ZX09732-001

This work was funded by Tianjin Key Medical Discipline (Specialty) Construction Project (Grant No. TJYXZDXK-009A), National Natural Science Foundation of China (Grant No. 82103677), and National Science and Technology Major Projects of China (Grant No. 2019ZX09732-001).

Cited By...

  • 7 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Cancer Biology & Medicine: 21 (7)
Cancer Biology & Medicine
Vol. 21, Issue 7
15 Jul 2024
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer
Ming Bai, Yao Lu, Chunmei Shi, Jianwei Yang, Wei Li, Xianli Yin, Chenghui Huang, Lin Shen, Liangzhi Xie, Yi Ba
Cancer Biology & Medicine Jul 2024, 21 (7) 636-650; DOI: 10.20892/j.issn.2095-3941.2023.0301

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer
Ming Bai, Yao Lu, Chunmei Shi, Jianwei Yang, Wei Li, Xianli Yin, Chenghui Huang, Lin Shen, Liangzhi Xie, Yi Ba
Cancer Biology & Medicine Jul 2024, 21 (7) 636-650; DOI: 10.20892/j.issn.2095-3941.2023.0301
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Conclusions
    • Supporting Information
    • Conflict of interest statement
    • Author contributions
    • Data availability statement
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Machine learning-based clinical decision support tool for advanced ESCC in the immunotherapy era: a multi-center study
  • Metabolic engineering of SLC38A2 reprograms glutamine utilization and enhances CAR-macrophage antitumor function in solid tumors
  • Multimodal artificial intelligence predicts PIK3CA mutation in breast cancer from digital pathology and clinical data: a multicenter study
Show more Original Article

Similar Articles

Subjects

  • Cancer immunology and immunotherapy
  • Gastrointestinal cancer

Keywords

  • colorectal cancer
  • SCT-I10A
  • SCT200
  • epidermal growth factor receptor
  • programmed cell death 1

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire